![Kari Grønås](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kari Grønås
Directeur/Membre du Conseil chez
SPAGO NANOMEDICAL AB
Profil
Kari Grønås is currently Chairman at Norwegian Cancer Society and Lungekreftforeningen.
Ms. Grønås is Director at Oncoinvent ASA since 2024, Independent Director at Spago Nanomedical AB since 2018, Managing Director & Director at K & K AS since 2012, and Director at Arxx Therapeutics AS.
Former roles include Chairman at Norwegian Pharmaceutical Society, Director at Oncopeptides AB, Lytix Biopharma AS, SoftOx.
Solutions AS, Ultimovacs ASA, and Oncoinvent ASA (Old).
Ms. Grønås was Independent Non-Executive Director at Oncoinvent ASA from 2016 to 2019 and Senior Vice President-Operations at Algeta ASA. Education includes a graduate degree from the University of Oslo.
Postes actifs de Kari Grønås
| Sociétés | Poste | Début |
|---|---|---|
| SPAGO NANOMEDICAL AB | Directeur/Membre du Conseil | 01/01/2018 |
| ONCOINVENT ASA | Directeur/Membre du Conseil | 01/01/2024 |
K & K AS
 K & K AS Miscellaneous Commercial ServicesCommercial Services Provides business and management consulting services | Directeur Général | 21/05/2012 |
Norwegian Cancer Society | Président | - |
Arxx Therapeutics AS
 Arxx Therapeutics AS BiotechnologyHealth Technology Develops therapeutics for fibrotic diseases | Directeur/Membre du Conseil | - |
Anciens postes connus de Kari Grønås
| Sociétés | Poste | Fin |
|---|---|---|
| ONCOINVENT ASA | Directeur/Membre du Conseil | 13/03/2019 |
Oncoinvent AS
 Oncoinvent AS Pharmaceuticals: MajorHealth Technology Develops alpha-emitting radiopharmaceuticals for cancer treatment | Directeur/Membre du Conseil | - |
| ONCOPEPTIDES AB | Directeur/Membre du Conseil | - |
Ultimovacs ASA
 Ultimovacs ASA Pharmaceuticals: MajorHealth Technology Develops novel peptide based therapeutic cancer vaccine | Directeur/Membre du Conseil | - |
| ░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Kari Grønås
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
52
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Oncopeptides AB
 Oncopeptides AB Pharmaceuticals: MajorHealth Technology Develops chemotherapeutic pharmaceuticals of compounds for cancer treatment | Health Technology |
University of Oslo
 University of Oslo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Engages in the development of products for the treatment of cancer | Health Technology |
Lytix Biopharma AS
 Lytix Biopharma AS Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company that develops novel cancer immunotherapies | Health Technology |
BerGenBio ASA
 BerGenBio ASA Pharmaceuticals: MajorHealth Technology Develops drugs for aggressive, drug resistant cancers | Health Technology |
Spago Nanomedical AB
 Spago Nanomedical AB BiotechnologyHealth Technology Acts as a biotechnology company | Health Technology |
Ultimovacs ASA
Ultimovacs ASA Pharmaceuticals: MajorHealth Technology Develops novel peptide based therapeutic cancer vaccine | Health Technology |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Develops alpha-emitting radiopharmaceuticals for cancer treatment | Health Technology |
Norwegian Pharmaceutical Society | |
SoftOx Solutions AS
 SoftOx Solutions AS Miscellaneous Commercial ServicesCommercial Services Develops and manufactures non-toxic & antiseptic medicines | Commercial Services |
K & K AS
K & K AS Miscellaneous Commercial ServicesCommercial Services Provides business and management consulting services | Commercial Services |
Norwegian Cancer Society | |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Develops therapeutics for fibrotic diseases | Health Technology |
